Jain Global LLC Increases Stock Holdings in Abbott Laboratories $ABT

Jain Global LLC boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 71.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 334,180 shares of the healthcare product maker’s stock after acquiring an additional 139,594 shares during the period. Abbott Laboratories accounts for about 0.2% of Jain Global LLC’s holdings, making the stock its 24th biggest position. Jain Global LLC’s holdings in Abbott Laboratories were worth $44,760,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of ABT. Cloud Capital Management LLC purchased a new stake in shares of Abbott Laboratories in the third quarter worth $29,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories during the third quarter worth about $31,000. Anfield Capital Management LLC increased its stake in Abbott Laboratories by 81.3% in the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares during the last quarter. Delos Wealth Advisors LLC purchased a new stake in shares of Abbott Laboratories in the 2nd quarter valued at about $32,000. Finally, Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories during the 3rd quarter valued at about $33,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. The trade was a 0.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Eric Shroff sold 709 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $81,946.22. Following the completion of the sale, the senior vice president owned 39,164 shares of the company’s stock, valued at $4,526,575.12. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is currently owned by corporate insiders.

Abbott Laboratories Stock Down 0.1%

Shares of NYSE ABT opened at $107.99 on Monday. The stock has a market capitalization of $187.66 billion, a P/E ratio of 29.03, a PEG ratio of 1.72 and a beta of 0.74. Abbott Laboratories has a one year low of $105.27 and a one year high of $139.06. The firm’s 50 day simple moving average is $114.58 and its two-hundred day simple moving average is $123.80. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same quarter in the prior year, the company earned $1.34 EPS. The firm’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is 67.74%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on ABT shares. Piper Sandler decreased their price objective on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research report on Friday, January 23rd. Evercore dropped their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Argus decreased their price target on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Leerink Partners lowered their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. Finally, Oppenheimer cut their target price on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $136.16.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.